{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:54:36Z","timestamp":1771332876880,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,4,12]],"date-time":"2016-04-12T00:00:00Z","timestamp":1460419200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s10620-016-4162-x","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T08:02:50Z","timestamp":1460620970000},"page":"2655-2665","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Ischemic Colitis as a Complication of Medication Use: An Analysis of the Federal Adverse Event Reporting System"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4972-6518","authenticated-orcid":false,"given":"Klaus","family":"Bielefeldt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,12]]},"reference":[{"key":"4162_CR1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cgh.2009.09.006","volume":"8","author":"GF Longstreth","year":"2010","unstructured":"Longstreth GF, Yao JF. Diseases and drugs that increase risk of acute large bowel ischemia. Clin Gastroenterol Hepatol. 2010;8:49\u201354.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4162_CR2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ajg.2014.395","volume":"110","author":"LJ Brandt","year":"2015","unstructured":"Brandt LJ, Feuerstadt P, Longstreth GF, et al. ACG clinical guideline: epidemiology, risk factors, patterns of presentation, diagnosis, and management of colon ischemia (CI). Am J Gastroenterol. 2015;110:18\u201344. (quiz 45).","journal-title":"Am J Gastroenterol"},{"key":"4162_CR3","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.jvs.2015.10.064","volume":"63","author":"Z Moghadamyeghaneh","year":"2016","unstructured":"Moghadamyeghaneh Z, Sgroi MD, Chen SL, et al. Risk factors and outcomes of postoperative ischemic colitis in contemporary open and endovascular abdominal aortic aneurysm repair. J Vasc Surg. 2016;63:866\u2013872. doi: 10.1016\/j.jvs.2015.10.064 .","journal-title":"J Vasc Surg"},{"key":"4162_CR4","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/ans.12134","volume":"83","author":"FF Viana","year":"2013","unstructured":"Viana FF, Chen Y, Almeida AA, et al. Gastrointestinal complications after cardiac surgery: 10-year experience of a single Australian centre. ANZ J Surg. 2013;83:651\u2013656.","journal-title":"ANZ J Surg"},{"key":"4162_CR5","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.avsg.2010.02.054","volume":"25","author":"S Darras","year":"2011","unstructured":"Darras S, Paineau J, Patra P, et al. Prognostic factors of ischemic colitis after infrarenal aortic surgery. Ann Vasc Surg. 2011;25:612\u2013619.","journal-title":"Ann Vasc Surg"},{"key":"4162_CR6","doi-asserted-by":"crossref","first-page":"761","DOI":"10.5009\/gnl15167","volume":"9","author":"SR Choi","year":"2015","unstructured":"Choi SR, Jee SR, Song GA, et al. Predictive factors for severe outcomes in ischemic colitis. Gut Liver. 2015;9:761\u2013766.","journal-title":"Gut Liver"},{"key":"4162_CR7","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1007\/s10620-012-2088-5","volume":"57","author":"T Kimura","year":"2012","unstructured":"Kimura T, Shinji A, Horiuchi A, et al. Clinical characteristics of young-onset ischemic colitis. Dig Dis Sci. 2012;57:1652\u20131659. doi: 10.1007\/s10620-012-2088-5 .","journal-title":"Dig Dis Sci"},{"key":"4162_CR8","doi-asserted-by":"crossref","first-page":"8042","DOI":"10.3748\/wjg.v19.i44.8042","volume":"19","author":"A Cosme","year":"2013","unstructured":"Cosme A, Montoro M, Santolaria S, et al. Prognosis and follow-up of 135 patients with ischemic colitis over a five-year period. World J Gastroenterol. 2013;19:8042\u20138046.","journal-title":"World J Gastroenterol"},{"key":"4162_CR9","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1091-255X(01)80067-6","volume":"5","author":"OA Preventza","year":"2001","unstructured":"Preventza OA, Lazarides K, Sawyer MD. Ischemic colitis in young adults: a single-institution experience. J Gastrointest Surg. 2001;5:388\u2013392.","journal-title":"J Gastrointest Surg"},{"key":"4162_CR10","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.cgh.2014.07.061","volume":"13","author":"S Yadav","year":"2015","unstructured":"Yadav S, Dave M, Edakkanambeth Varayil J, et al. A population-based study of incidence, risk factors, clinical spectrum, and outcomes of ischemic colitis. Clin Gastroenterol Hepatol. 2015;13:731\u2013738. (e1-6; quiz e41).","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4162_CR11","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1572-0241.2006.00459.x","volume":"101","author":"L Chang","year":"2006","unstructured":"Chang L, Chey WD, Harris L, et al. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol. 2006;101:1069\u20131079.","journal-title":"Am J Gastroenterol"},{"key":"4162_CR12","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/ajg.2010.25","volume":"105","author":"L Chang","year":"2010","unstructured":"Chang L, Tong K, Ameen V. Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. Am J Gastroenterol. 2010;105:866\u2013875.","journal-title":"Am J Gastroenterol"},{"key":"4162_CR13","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1111\/j.1572-0241.2004.30509.x","volume":"99","author":"WD Chey","year":"2004","unstructured":"Chey WD, Chey WY, Heath AT, et al. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2004;99:2195\u20132203.","journal-title":"Am J Gastroenterol"},{"key":"4162_CR14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1001\/archinte.162.1.101","volume":"162","author":"DM Lisi","year":"2002","unstructured":"Lisi DM. Lotronex withdrawal. Arch Intern Med. 2002;162:101.","journal-title":"Arch Intern Med"},{"key":"4162_CR15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2982.2007.01015.x","volume":"20","author":"L Chang","year":"2008","unstructured":"Chang L, Kahler KH, Sarawate C, et al. Assessment of potential risk factors associated with ischaemic colitis. Neurogastroenterol Motil. 2008;20:36\u201342.","journal-title":"Neurogastroenterol Motil"},{"key":"4162_CR16","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cgh.2006.02.017","volume":"4","author":"EMM Quigley","year":"2006","unstructured":"Quigley EMM, Wald A, Fidelholtz J, et al. Safety and tolerability of tegaserod in patients with chronic constipation: pooled data from two phase III studies. Clin Gastroenterol Hepatol. 2006;4:605\u2013613.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4162_CR17","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1111\/j.1572-0241.2006.00789.x","volume":"101","author":"S Muller-Lissner","year":"2006","unstructured":"Muller-Lissner S, Kamm MA, Musoglu A, et al. Safety, tolerability, and efficacy of tegaserod over 13\u00a0months in patients with chronic constipation. Am J Gastroenterol. 2006;101:2558\u20132569. (quiz 2671).","journal-title":"Am J Gastroenterol"},{"key":"4162_CR18","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1592\/phco.25.4.620.61032","volume":"25","author":"JK DiBaise","year":"2005","unstructured":"DiBaise JK. Tegaserod-associated ischemic colitis. Pharmacotherapy. 2005;25:620\u2013625.","journal-title":"Pharmacotherapy"},{"key":"4162_CR19","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1503\/cmaj.1040882","volume":"170","author":"E Wooltorton","year":"2004","unstructured":"Wooltorton E. Tegaserod (Zelnorm) for irritable bowel syndrome: reports of serious diarrhea and intestinal ischemia. Cand Med Assoc J. 2004;170:1908.","journal-title":"Cand Med Assoc J"},{"key":"4162_CR20","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2036.2012.05011.x","volume":"35","author":"J Tack","year":"2012","unstructured":"Tack J, Camilleri M, Chang L, et al. Systematic review: cardiovascular safety profile of 5-HT4 agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012;35:745\u2013767.","journal-title":"Aliment Pharmacol Ther"},{"key":"4162_CR21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1053\/j.gastro.2006.11.002","volume":"132","author":"MD Gershon","year":"2007","unstructured":"Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007;132:397\u2013414.","journal-title":"Gastroenterology"},{"key":"4162_CR22","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0165-0327(98)00221-3","volume":"51","author":"SM Stahl","year":"1998","unstructured":"Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors: serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord. 1998;51:215\u2013235.","journal-title":"J Affect Disord"},{"key":"4162_CR23","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1017\/S1092852900019726","volume":"10","author":"SM Stahl","year":"2005","unstructured":"Stahl SM, Grady MM, Moret C, et al. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005;10:732\u2013747.","journal-title":"CNS Spectr"},{"key":"4162_CR24","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ana.22292","volume":"69","author":"MS Asghar","year":"2011","unstructured":"Asghar MS, Hansen AE, Amin FM, et al. Evidence for a vascular factor in migraine. Ann Neurol. 2011;69:635\u2013645.","journal-title":"Ann Neurol"},{"key":"4162_CR25","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1001\/archinte.158.17.1946","volume":"158","author":"JF Knudsen","year":"1998","unstructured":"Knudsen JF, Friedman B, Chen M, et al. Ischemic colitis and sumatriptan use. Arch Intern Med. 1998;158:1946\u20131948.","journal-title":"Arch Intern Med"},{"key":"4162_CR26","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/00000542-200003000-00040","volume":"92","author":"V Bosek","year":"2000","unstructured":"Bosek V, Hu P, Robinson LA. Acute myocardial ischemia after administration of ondansetron hydrochloride. Anesthesiology. 2000;92:885\u2013887.","journal-title":"Anesthesiology"},{"key":"4162_CR27","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/1751-2980.12045","volume":"14","author":"M Mosli","year":"2013","unstructured":"Mosli M, Parfitt J, Gregor J. Retrospective analysis of disease association and outcome in histologically confirmed ischemic colitis. J Dig Dis. 2013;14:238\u2013243.","journal-title":"J Dig Dis"},{"key":"4162_CR28","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/1751-2980.12182","volume":"15","author":"M Sherid","year":"2014","unstructured":"Sherid M, Sifuentes H, Samo S, et al. Ischemic colitis: A forgotten entity. Results of a retrospective study in 118 patients. J Dig Dis. 2014;15:606\u2013613.","journal-title":"J Dig Dis"},{"key":"4162_CR29","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1111\/j.1463-1318.2012.03171.x","volume":"14","author":"S O\u2019Neill","year":"2012","unstructured":"O\u2019Neill S, Yalamarthi S. Systematic review of the management of ischaemic colitis. Colorectal Dis. 2012;14:e751\u2013e763.","journal-title":"Colorectal Dis"},{"key":"4162_CR30","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1111\/j.1572-0241.2001.03927.x","volume":"96","author":"DK Wysowski","year":"2001","unstructured":"Wysowski DK, Corken A, Gallo-Torres H, et al. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and food and drug administration regulatory actions. Am J Gastroenterol. 2001;96:1698\u20131703.","journal-title":"Am J Gastroenterol"},{"key":"4162_CR31","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1053\/j.gastro.2007.04.057","volume":"132","author":"P Pasricha","year":"2007","unstructured":"Pasricha P. Desperately seeking serotonin\u2026 A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders. Gastroenterology. 2007;132:2287\u20132290.","journal-title":"Gastroenterology"},{"key":"4162_CR32","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00005344-200302000-00021","volume":"41","author":"H Gul","year":"2003","unstructured":"Gul H, Yildiz O, Simsek A, et al. Pharmacologic characterization of contractile serotonergic receptors in human isolated mesenteric artery. J Cardiovasc Pharmacol. 2003;41:307\u2013315.","journal-title":"J Cardiovasc Pharmacol"},{"key":"4162_CR33","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1124\/pr.111.004697","volume":"64","author":"SW Watts","year":"2012","unstructured":"Watts SW, Morrison SF, Davis RP, et al. Serotonin and blood pressure regulation. Pharmacol Rev. 2012;64:359\u2013388.","journal-title":"Pharmacol Rev"},{"key":"4162_CR34","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00002018-200326020-00003","volume":"26","author":"G Nappi","year":"2003","unstructured":"Nappi G, Sandrini G, Sances G. Tolerability of the triptans: clinical implications. Drug Saf. 2003;26:93\u2013107.","journal-title":"Drug Saf"},{"key":"4162_CR35","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1517\/14656566.2010.522567","volume":"11","author":"S Barra","year":"2010","unstructured":"Barra S, Lanero S, Madrid A, et al. Sumatriptan therapy for headache and acute myocardial infarction. Expert Opin Pharmacother. 2010;11:2727\u20132737.","journal-title":"Expert Opin Pharmacother"},{"key":"4162_CR36","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1038\/ajg.2009.356","volume":"104","author":"AA Alkhatib","year":"2009","unstructured":"Alkhatib AA, Gangotena F, Peterson KA. Rizatriptan induced acute on top of chronic ischemic colitis. Am J Gastroenterol. 2009;104:2643\u20132644.","journal-title":"Am J Gastroenterol"},{"key":"4162_CR37","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1345\/aph.1L544","volume":"43","author":"PL Havrilla","year":"2009","unstructured":"Havrilla PL, Kane-Gill SL, Verrico MM, et al. Coronary vasospasm and atrial fibrillation associated with ondansetron therapy. Ann Pharmacother. 2009;43:532\u2013536.","journal-title":"Ann Pharmacother"},{"key":"4162_CR38","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/bcp.12383","volume":"78","author":"SW Oh","year":"2014","unstructured":"Oh SW, Kim J, Myung SK, et al. Antidepressant use and risk of coronary heart disease: meta-analysis of observational studies. Br J Clin Pharmacol. 2014;78:727\u2013737.","journal-title":"Br J Clin Pharmacol"},{"key":"4162_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15280","volume":"15","author":"CA Coupland","year":"2011","unstructured":"Coupland CA, Dhiman P, Barton G, et al. A study of the safety and harms of antidepressant drugs for older people: a cohort study using a large primary care database. Health Technol Assess. 2011;15:1\u2013202. (iii\u2013iv).","journal-title":"Health Technol Assess"},{"key":"4162_CR40","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.vph.2012.11.002","volume":"58","author":"DT Beattie","year":"2013","unstructured":"Beattie DT, Higgins DL, Ero MP, et al. An in vitro investigation of the cardiovascular effects of the 5-HT(4) receptor selective agonists, velusetrag and TD-8954. Vasc Pharmacol. 2013;58:150\u2013156.","journal-title":"Vasc Pharmacol"},{"key":"4162_CR41","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejphar.2009.07.010","volume":"619","author":"KY Chan","year":"2009","unstructured":"Chan KY, de Vries R, Leijten FP, et al. Functional characterization of contractions to tegaserod in human isolated proximal and distal coronary arteries. Eur J Pharmacol. 2009;619:61\u201367.","journal-title":"Eur J Pharmacol"},{"key":"4162_CR42","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/j.1476-5381.2009.00392.x","volume":"158","author":"E Painsipp","year":"2009","unstructured":"Painsipp E, Shahbazian A, Holzer P. Alosetron, cilansetron and tegaserod modify mesenteric but not colonic blood flow in rats. Br J Pharmacol. 2009;158:1210\u20131226.","journal-title":"Br J Pharmacol"},{"key":"4162_CR43","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00210-011-0687-x","volume":"385","author":"DL Higgins","year":"2012","unstructured":"Higgins DL, Ero MP, Loeb M, et al. The inability of tegaserod to affect platelet aggregation and coronary artery tone at supratherapeutic concentrations. Naunyn Schmiedebergs Arch Pharmacol. 2012;385:103\u2013109.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"4162_CR44","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/MJT.0b013e3181b63f21","volume":"17","author":"VL Serebruany","year":"2010","unstructured":"Serebruany VL, El Mouelhi M, Pfannkuche HJ, et al. Investigations on 5-HT(4) receptor expression and effects of tegaserod on human platelet aggregation in vitro. Am J Ther. 2010;17:543\u2013552.","journal-title":"Am J Ther"},{"key":"4162_CR45","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1161\/01.CIR.0000127578.21885.3E","volume":"109","author":"DH Solomon","year":"2004","unstructured":"Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004;109:2068\u20132073.","journal-title":"Circulation"},{"key":"4162_CR46","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00004836-199301000-00009","volume":"16","author":"R Carratu","year":"1993","unstructured":"Carratu R, Parisi P, Agozzino A. Segmental ischemic colitis associated with nonsteroidal antiinflammatory drugs. J Clin Gastroenterol. 1993;16:31\u201334.","journal-title":"J Clin Gastroenterol"},{"key":"4162_CR47","doi-asserted-by":"crossref","first-page":"5828","DOI":"10.3748\/wjg.v11.i37.5828","volume":"11","author":"M Stolte","year":"2005","unstructured":"Stolte M, Karimi D, Vieth M, et al. Strictures, diaphragms, erosions or ulcerations of ischemic type in the colon should always prompt consideration of nonsteroidal anti-inflammatory drug-induced lesions. World J Gastroenterol. 2005;11:5828\u20135833.","journal-title":"World J Gastroenterol"},{"key":"4162_CR48","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/BF02235589","volume":"43","author":"A Puspok","year":"2000","unstructured":"Puspok A, Kiener HP, Oberhuber G. Clinical, endoscopic, and histologic spectrum of nonsteroidal anti-inflammatory drug-induced lesions in the colon. Dis Colon Rectum. 2000;43:685\u2013691.","journal-title":"Dis Colon Rectum"},{"key":"4162_CR49","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/pds.1820","volume":"18","author":"CL Roumie","year":"2009","unstructured":"Roumie CL, Choma NN, Kaltenbach L, et al. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease. Pharmacoepidemiol Drug Saf. 2009;18:1053\u20131063.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4162_CR50","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/pds.1339","volume":"16","author":"E Rahme","year":"2007","unstructured":"Rahme E, Watson DJ, Kong SX, et al. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study. Pharmacoepidemiol Drug Saf. 2007;16:493\u2013503.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4162_CR51","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/pds.1801","volume":"18","author":"H Peyriere","year":"2009","unstructured":"Peyriere H, Roux C, Ferard C, et al. Antipsychotics-induced ischaemic colitis and gastrointestinal necrosis: a review of the French pharmacovigilance database. Pharmacoepidemiol Drug Saf. 2009;18:948\u2013955.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4162_CR52","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1177\/0269881113482530","volume":"27","author":"JY Shin","year":"2013","unstructured":"Shin JY, Choi NK, Jung SY, et al. Risk of ischemic stroke with the use of risperidone, quetiapine and olanzapine in elderly patients: a population-based, case-crossover study. J Psychopharmacol. 2013;27:638\u2013644.","journal-title":"J Psychopharmacol"},{"key":"4162_CR53","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/eurheartj\/ehu263","volume":"36","author":"R Brauer","year":"2015","unstructured":"Brauer R, Smeeth L, Anaya-Izquierdo K, et al. Antipsychotic drugs and risks of myocardial infarction: a self-controlled case series study. Eur Heart J. 2015;36:984\u2013992.","journal-title":"Eur Heart J"},{"key":"4162_CR54","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.biopsych.2012.07.006","volume":"73","author":"CS Wu","year":"2013","unstructured":"Wu CS, Wang SC, Gau SS, et al. Association of stroke with the receptor-binding profiles of antipsychotics\u2014a case-crossover study. Biol Psychiatry. 2013;73:414\u2013421.","journal-title":"Biol Psychiatry"},{"key":"4162_CR55","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1176\/appi.ajp.2012.12050599","volume":"170","author":"C Crump","year":"2013","unstructured":"Crump C, Winkleby MA, Sundquist K, et al. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry. 2013;170:324\u2013333.","journal-title":"Am J Psychiatry"},{"key":"4162_CR56","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.3748\/wjg.v20.i13.3698","volume":"20","author":"SO Lee","year":"2014","unstructured":"Lee SO, Kim SH, Jung SH, et al. Colonoscopy-induced ischemic colitis in patients without risk factors. World J Gastroenterol. 2014;20:3698\u20133702.","journal-title":"World J Gastroenterol"},{"key":"4162_CR57","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1055\/s-2007-1001302","volume":"30","author":"MI Cremers","year":"1998","unstructured":"Cremers MI, Oliveira AP, Freitas J. Ischemic colitis as a complication of colonoscopy. Endoscopy. 1998;30:S54.","journal-title":"Endoscopy"},{"key":"4162_CR58","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1053\/gast.2001.21177","volume":"120","author":"D Friedel","year":"2001","unstructured":"Friedel D, Thomas R, Fisher RS. Ischemic colitis during treatment with alosetron. Gastroenterology. 2001;120:557\u2013560.","journal-title":"Gastroenterology"},{"key":"4162_CR59","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1345\/aph.1R526","volume":"47","author":"A Salk","year":"2013","unstructured":"Salk A, Stobaugh DJ, Deepak P, et al. Ischemic colitis with type I interferons used in the treatment of hepatitis C and multiple sclerosis: an evaluation from the food and drug administration adverse event reporting system and review of the literature. Ann Pharmacother. 2013;47:537\u2013542.","journal-title":"Ann Pharmacother"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-016-4162-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-016-4162-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-016-4162-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T19:00:55Z","timestamp":1718478055000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-016-4162-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,12]]},"references-count":59,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["4162"],"URL":"https:\/\/doi.org\/10.1007\/s10620-016-4162-x","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,12]]}}}